Clinical Trials Directory

Trials / Completed

CompletedNCT04027803

Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®

A Double-blind, Randomized Clinical Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 (JSC BIOCAD, Russia) and Soliris® in Healthy Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
78 (actual)
Sponsor
Biocad · Industry
Sex
Male
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

A Double-blind, Randomized Clinical Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 (JSC BIOCAD, Russia) and Soliris® in Healthy Volunteers

Conditions

Interventions

TypeNameDescription
BIOLOGICALBCD-148single intravenous infusion of BCD-148 (900 mg)
BIOLOGICALSolirissingle intravenous infusion of Soliris (900 mg)

Timeline

Start date
2018-09-21
Primary completion
2019-04-07
Completion
2019-04-07
First posted
2019-07-22
Last updated
2020-05-15
Results posted
2020-05-15

Locations

1 site across 1 country: Russia

Source: ClinicalTrials.gov record NCT04027803. Inclusion in this directory is not an endorsement.

Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-1 (NCT04027803) · Clinical Trials Directory